Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ABB C1 Supplement in Allergic Patients Undergoing Immunotherapy
NCT06448585Phase 4Completed
- Sponsor
- Gala Servicios Clínicos
- Start
- May 2024
- Primary completion
- May 2024
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial (4 arms), sponsored by Gala Servicios Clínicos. Primary endpoints: Total Immunoglobulin E at Day 180, Specific Immunoglobulin E at Day 180 and 1 more. Started May 2024; status: completed.
Beyond the preview
Go deeper on NCT06448585.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06448585.